Head-To-Head Contrast: Trillium Therapeutics (TRIL) & Mateon Therapeutics (MATN)
Trillium Therapeutics (NASDAQ: TRIL) and Mateon Therapeutics (NASDAQ:MATN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, earnings, risk, analyst recommendations, dividends and valuation.
This table compares Trillium Therapeutics and Mateon Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
45.1% of Trillium Therapeutics shares are held by institutional investors. Comparatively, 8.6% of Mateon Therapeutics shares are held by institutional investors. 2.3% of Mateon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This is a breakdown of recent ratings and target prices for Trillium Therapeutics and Mateon Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Trillium Therapeutics presently has a consensus price target of $16.50, suggesting a potential upside of 279.31%. Mateon Therapeutics has a consensus price target of $2.00, suggesting a potential upside of 459.13%. Given Mateon Therapeutics’ higher possible upside, analysts clearly believe Mateon Therapeutics is more favorable than Trillium Therapeutics.
Risk & Volatility
Trillium Therapeutics has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. Comparatively, Mateon Therapeutics has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500.
Valuation & Earnings
This table compares Trillium Therapeutics and Mateon Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Trillium Therapeutics||N/A||N/A||-$25.72 million||($3.49)||-1.25|
|Mateon Therapeutics||N/A||N/A||-$14.36 million||($0.54)||-0.66|
Trillium Therapeutics is trading at a lower price-to-earnings ratio than Mateon Therapeutics, indicating that it is currently the more affordable of the two stocks.
Mateon Therapeutics Company Profile
Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor’s blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA.
Receive News & Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.